Ironwood Pharmaceuticals | IRWD - Selling And Administration Expenses


Ironwood Pharmaceuticals reported $33.33M in Selling and Administration Expenses for its fiscal quarter ending in December of 2024.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
Agios Pharmaceuticals USD 41.27M 4.6M Sep/2025
Alnylam Pharmaceuticals USD 262.59M 60.72M Sep/2025
Amarin USD 17.94M 17.86M Sep/2025
Ardelyx USD 83.61M 378K Sep/2025
Astellas Pharma JPY 206.84B 9.84B Sep/2025
AstraZeneca USD 148M 4.86B Sep/2025
Charles River Laboratories USD 177.59M 8.23M Sep/2025
Exact Sciences USD 491.64M 35.94M Sep/2025
Halozyme Therapeutics USD 37.53M 4.53M Sep/2025
Incyte USD 329.08M 1.94M Sep/2025
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
MacroGenics USD 9.9M 600K Sep/2025
Moderna USD 268M 38M Sep/2025
Myriad Genetics USD 129M 1.3M Sep/2025
Pacira USD 91.8M 14.6M Sep/2025
PTC Therapeutics USD 84.05M 1.22M Sep/2025
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
Takeda JPY 282.78B 29.23B Dec/2025
Ultragenyx Pharmaceutical USD 86.62M 26K Sep/2025